SCHEMBL6977119

SCHEMBL6977119

CC(C)(CNC(=O)c1cc(C#N)ccc1Cl)c1coc(-c2ccc(F)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.47
HDAC1 Q13547 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
GRM5 P41594 2/20 0.40
CETP P11597 5/20 0.39
HDAC6 Q9UBN7 1/20 0.38
P2RX7 Q99572 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EGLN2 Q96KS0 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6977222 0.85 HDAC1 (0.48) PPARGHDAC1HDAC8HDAC4HDAC7
SCHEMBL2226035 0.85 HDAC1 (0.48) PPARGHDAC1HDAC8HDAC4HDAC7
SCHEMBL14752491 0.82 HDAC1 (0.53) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14672169 0.80 HDAC4 (0.67) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL2267220 0.74 HDAC8 (0.42) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL2274396 0.74 HDAC8 (0.41) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752470 0.73 HDAC4 (0.55) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL6977857 0.71 HDAC4 (0.69) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752480 0.70 HDAC4 (0.52) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752493 0.69 HDAC4 (0.71) HDAC1HDAC8HDAC4HDAC7HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 EP disclosed
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 EP disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY PPARG 2431/4885HDAC1 640/4885HDAC8 1583/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY PPARG 2431/4885HDAC1 640/4885HDAC8 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.